Deals

Compugen Closes $63M CMPO at 26% Discount via Jefferies-led Syndicate

By |

Compugen Limited (CGEN) announced that it has raised $63,000,000 in a CMPO/Overnight transaction. The common stock was sold at $10.50 per share, an approximate 26% discount to the market price ($14.20) of CGEN at deal announcement. Jefferies & Company acted as the Sole Book-Running Manager with JMP Securities, Oppenheimer, and Chardan Capital Markets as Co-Managers and Torreya Capital as Financial Advisor on the transaction. Underwriter counsel was Goodwin Procter and Gornitzky & Co. and issuer counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo and Tulchinsky Stern Marciano Cohen Levitsky.

Deals

Neptune Technologies Closes $25M CMPO at 16% Discount via Roth Capital, Euro Pacific, National Securities

By |

Neptune Technologies & Bioressources Inc. (NEPT) announced that it has raised $25,000,000 in a CMPO/Overnight transaction. The common stock was sold at $2.50 per share, an approximate 16% discount to the market price ($2.98) of NEPT at deal announcement. Roth Capital Partners and Euro Pacific Canada, Inc. acted as Joint Book-Running Managers and National Securities Corporation acted as Lead Manager on the transaction. Underwriter counsel was Morrison & Foerster, LLP and Stikeman Elliott LLP and issuer counsel was Osler, Hoskin & Harcourt LLP. Note this Placement is subject to customary closing conditions and is expected to close on 03/05/2014.

Deals

VolitionRX Raises $3M at 25% Discount from JEB Partners

By |

VolitionRX Limited (VNRX) announced that it has raised $3,000,000 in a Common Stock transaction. The common stock was sold at $2.00 per share, an approximate 25% discount to the market price ($2.67) of VNRX at deal announcement. A series of 1,500,000 60-Month Warrants with an exercise price of $2.20 per share (17.6% discount) was issued to the investors in this transaction. Lake Street Capital Markets, Founding Asset Management, and MZ Advisory Pte acted as agents on the transaction. The investors include JEB Partners, LP.

Deals

Marina Biotech Raises $6M in Conv Preferred Deal at 41% Discount

By |

Marina Biotech, Inc. (MRNA) announced that it has raised $6,000,000 in a Convertible Preferred Stock transaction. The fixed conversion price of the Convertible Preferred Stock is $0.75 per share, an approximate 40.94% discount to the market price ($1.27) of MRNA at deal announcement. A series of 6,000,000 60-Month Warrants with an exercise price of $0.75 per share (40.94% discount) was issued to the investors in this transaction. Note this Placement is subject to customary closing conditions and is expected to close by 03/07/2014. via PlacementTracker.